BackAdaptive Biotechnologies Overview

Adaptive Biotechnologies Long Term Debt

Latest long-term debt for ADPT: $190M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$193.86M

Peer average

Loading

Adaptive Biotechnologies Long Term Debt History

Loading

Adaptive Biotechnologies vs. peers: Long Term Debt Comparison

Loading

Adaptive Biotechnologies Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Adaptive Biotechnologies (ADPT) FAQ

Adaptive Biotechnologies (ADPT) currently reports a long-term debt of $190M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Adaptive Biotechnologies's long-term debt history and peer comparisons.

Adaptive Biotechnologies's long-term debt changed from $0 to $190M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptive Biotechnologies reported $190M in long-term debt as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptive Biotechnologies, and consider following ADPT for alerts when major investors trade the stock.

Adaptive Biotechnologies is classified in the Healthcare sector. On long-term debt, it currently shows $190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADPT with unrelated industries.